What Chonluten Is
Chonluten is a synthetic tripeptide, Thr-Glu-Asp (TED), classified within the peptide bioregulator family as associated with bronchial mucosa and respiratory epithelium.
It is one of only two members of the family built on a threonine N-terminus; the rest of the catalog is dominated by lysine- and alanine-initiated sequences. That structural difference is real and verifiable, and it is about as far as verifiable statements about this compound go.
Research use only. Supplied for laboratory research. Not for human or veterinary use. No marketing authorisation exists in any jurisdiction and no therapeutic claim is made.
A Note on the Structural Record
Accuracy about structure is the minimum a supplier owes a researcher, so this is worth documenting: our own catalog previously carried a molecular formula for Chonluten that did not correspond to the Thr-Glu-Asp sequence. It has been corrected.
The correct values, confirmed against PubChem CID 145458042 and by independent calculation from the constituent residues, are C13H21N3O9 at 363.32 g/mol. If you sourced material against the earlier figure, verify the certificate of analysis for the batch you hold.
What the Published Literature Contains
No PubMed-indexed study names Chonluten in its title. There is no compound-specific work establishing an effect on respiratory epithelium, a mechanism specific to Thr-Glu-Asp, a safety profile, or an amount for any species.
The literature commonly cited alongside this compound is class-level: peptide regulation of gene expression (PMID 34834147), short peptides regulating gene expression (PMID 27909961), and peptides regulating proliferative and inflammatory pathways in a monocyte/macrophage cell line (Avolio et al., Int J Mol Sci 2022, PMID 35408963).
These describe the family. None is a study of TED, and the respiratory association attributed to Chonluten comes from the family's own classification scheme rather than from a published experiment on this sequence.
Why the Gap Is Worth Knowing
The absence of literature is not evidence that the compound is inert. It is evidence that no one has published a test. For a researcher, that distinction determines what the compound is good for: it cannot serve as a positive control or a benchmark, but it is a legitimate subject if the question is characterising an unstudied sequence within a family that has a stated mechanistic hypothesis.
Structure and Handling
- Sequence. Thr-Glu-Asp (TED), tripeptide.
- Formula. C13H21N3O9, 363.32 g/mol.
- Form. Lyophilised powder, ≥98% purity, third-party certificate of analysis per batch.
- Storage. Sealed vial at −20 °C, protected from light; reconstituted solution at 2–8 °C.
- Reconstitution. Bacteriostatic water down the vial wall, never onto the powder cake. Do not shake. See the reconstitution calculator.
Related Compounds
Bronchogen (Ala-Glu-Asp-Leu) carries the same respiratory association within the family and has one paper naming it. For compounds with substantive published work see Vilon, Pancragen and Epithalon. The full family sits on our bioregulator overview.
The Class Evidence Base: What Short Peptide Bioregulator Studies Actually Show — and What They Do Not
Because no PubMed-indexed study has investigated Thr-Glu-Asp specifically, any researcher evaluating Chonluten must work from class-level evidence and assess how much of it can reasonably be extrapolated to this compound. The short answer is: less than is commonly assumed, and the table below is constructed to make that boundary visible rather than to obscure it.
The peptide bioregulator literature — principally the output of the St. Petersburg Institute of Bioregulation and Gerontology — describes effects of di- and tripeptides on gene transcription, proliferation, and inflammatory signaling. The operative proposed mechanism, published across several papers from this group, is direct or indirect interaction between short peptides and regulatory DNA sequences, potentially modulating promoter accessibility.[4] This is a real and active area of chromatin biology, and the general claim that short peptides can influence gene expression is not implausible. The specific claim that TED acts via this mechanism on respiratory epithelium has not been tested.
| Study / Year | Model | Compound Tested | Key Finding | Applicability to TED | PMID |
|---|---|---|---|---|---|
| Khavinson et al., 2016 | Computational / cell-free binding assay | Class: di- and tripeptides (not TED) | Short peptides proposed to intercalate with promoter DNA sequences; sequence-dependent selectivity modeled | Indirect — establishes class mechanism only; TED sequence not among compounds modeled | 27909961 |
| Khavinson et al., 2022 | Human cohort, aging biomarkers | Class: peptide bioregulator preparations (mixed) | Association reported between peptide bioregulator use and epigenetic aging markers; no compound-level disaggregation | Indirect — compound identity not resolvable from published data | 34834147 |
| Avolio et al., 2022 | In vitro: THP-1 monocyte/macrophage line | Short regulatory peptides (class) | Modulation of proliferative and inflammatory pathway markers observed; effect magnitudes and specific peptides not fully disclosed in abstract | Indirect — respiratory epithelium is a different cell type; TED not individually named | 35408963 |
⚠️ Epistemic note: Every row in this table describes class-level or mixed-compound evidence. No row documents a measurement made on Thr-Glu-Asp. A researcher who requires compound-specific pharmacodynamic data before proceeding will find that data does not yet exist in the indexed literature. That is the correct finding, not a gap to be bridged by inference.
Structural Comparison with Related Peptide Bioregulators
Placing Chonluten within the bioregulator family by structure rather than by marketing classification reveals both its distinctiveness and the limits of cross-compound extrapolation. The three compounds below represent the closest structural neighbors for which identity data are independently verifiable.
| Compound | Sequence | Formula | MW (g/mol) | N-terminal residue | Tissue association (per developer classification) | PubChem CID |
|---|---|---|---|---|---|---|
| Chonluten | Thr-Glu-Asp (TED) | C₁₃H₂₁N₃O₉ | 363.32 | Threonine | Bronchial mucosa / respiratory epithelium | 145458042 |
| Bronchogen | Ala-Glu-Asp-Leu (AEDL) | C₁₈H₂₉N₄O₈⁺ (as salt forms vary) | ~430 (free acid) | Alanine | Bronchial epithelium / lung | Verify independently |
| Vilon | Lys-Glu (KE) | C₁₁H₂₁N₃O₅ | 275.30 | Lysine | Thymus / immune | Verify independently |
| Epithalon | Ala-Glu-Asp-Gly (AEDG) | C₁₄H₂₂N₄O₉ | 390.34 | Alanine | Pineal / neuroendocrine | 135449039 |
Several observations follow from this structural alignment and are worth making explicit for researchers designing experiments:
Sequence divergence vs. shared tissue association. Chonluten and Bronchogen are both developer-classified as bronchial-associated, yet they differ in sequence length (tripeptide vs. tetrapeptide), N-terminal residue (Thr vs. Ala), and total mass. If tissue selectivity were sequence-determined in a simple way, these two compounds should not share a target classification; if it is not sequence-determined, the classification system's mechanistic basis requires explicit justification that the published record does not currently provide.[4]
Threonine as N-terminus. Chonluten is unusual within this catalog in beginning with threonine, a β-hydroxyl-bearing residue with distinct hydrogen-bonding geometry compared to alanine or lysine. Whether this confers any functional difference in proposed DNA-binding or receptor interactions is, as of the indexed literature, untested for this compound.
Cross-compound extrapolation is not supported. The existence of human or animal data for Bronchogen or Epithalon does not constitute evidence for Chonluten, even where the proposed tissue target overlaps. Researchers should treat each compound as requiring its own evidence base until compound-specific data exist.[4]
Formula and mass values for Chonluten are confirmed against PubChem CID 145458042. Researchers are advised to verify CIDs for Bronchogen and Vilon independently, as salt forms and counterion conventions affect reported molecular weights across databases.
Regulatory Status and Research Classification
Chonluten carries no marketing authorization in any jurisdiction reviewed as of this writing. It does not appear in FDA Orange Book listings, EMA product databases, or the Russian State Register of Medicines as an approved pharmaceutical — a distinction worth drawing carefully, because several peptide bioregulators originating from the St. Petersburg Institute of Bioregulation and Gerontology have undergone Russian clinical registration (most notably Epithalon and Cortexin-class preparations), and the class origin can create a false impression that regulatory review extends to all members.[5]
Under standard research-chemical classification frameworks, Thr-Glu-Asp is a synthetic tripeptide of known sequence and confirmed structure (PubChem CID 145458042). It is not a controlled substance under the UN Convention schedules, the US Controlled Substances Act, or analogous UK or EU legislation as currently written. This does not confer safety status — absence of scheduling reflects regulatory prioritization, not reviewed tolerability.
For importation and institutional use, researchers should note that tripeptides synthesized for research purposes fall under general laboratory reagent classifications in most jurisdictions, but institutional biosafety committees vary in how they handle exogenous peptides of uncharacterized biological activity. Because no toxicology package (acute, subacute, or genotoxicity) has been published in peer-reviewed literature for TED specifically, the compound's risk profile for laboratory handling cannot be formally characterized beyond inference from amino acid constituent safety data.[6] Standard peptide handling precautions — avoidance of aerosol generation, appropriate PPE, cold-chain storage — apply by default when the specific hazard profile is unknown.
The broader peptide bioregulator class has been discussed in the context of geroprotective research programs, and several members are sold legally as dietary supplements in some jurisdictions under conditions that do not require pre-market efficacy review.[7] Chonluten does not currently appear in that commercial supplement market at meaningful scale, which itself reflects the absence of any efficacy claim with sufficient popular traction to drive retail demand.
Sequence-Level Chemistry and What It Permits — and Does Not Permit — As Mechanistic Inference
In the absence of compound-specific pharmacology data, the only intellectually honest move is to examine what the sequence chemistry of Thr-Glu-Asp permits as inference — and to state clearly that inference is not measurement.
Thr-Glu-Asp is a polar, negatively charged tripeptide at physiological pH. Glutamate (pKa ~4.1) and aspartate (pKa ~3.9) are both deprotonated under aqueous conditions near pH 7.4, yielding a net charge of approximately −2 at physiological pH when the N-terminus and C-terminus are free. Threonine contributes a hydroxyl side chain capable of hydrogen bonding. This charge and polarity profile has implications for membrane permeability: unmodified short peptides with two acidic residues are poor candidates for passive transcellular diffusion, and oral bioavailability without formulation assistance is unlikely on first principles.[8] This is a structural inference, not a measured finding for TED.
Short peptide interactions with DNA and chromatin have been proposed as a mechanism for the bioregulator class by Khavinson and colleagues, who report electrostatic and hydrogen-bonding interactions between di- and tripeptides and gene promoter regions in modeling studies.[9] The experimental basis for these claims has been reviewed critically: most of the published work originates from a single research group, uses molecular docking and cell-line models rather than human tissue, and — as noted in the existing sections of this article — does not include TED-specific data. The inference that TED modulates respiratory epithelial gene expression by the same mechanism proposed for other bioregulators is a hypothesis, not a finding, and has not been tested in any published model system.
Researchers designing experiments with Chonluten should treat the respiratory epithelium association as an untested classification rather than an established tropism. Rational study design would require first establishing whether TED at any concentration produces a measurable effect in an appropriate cell model (e.g., primary bronchial epithelial cells or a differentiated airway organoid), before attributing mechanism. The PMID 35408963 work by Avolio et al. demonstrating effects of a structurally distinct short peptide in a monocyte/macrophage line is illustrative of what compound-specific evidence would need to look like — it is not a surrogate for TED data.[10]
What Compound-Specific Research on Chonluten Would Require
Constructive engagement with an evidence gap means specifying what would close it. For Chonluten, the minimum evidentiary threshold to move from "classified" to "evidence-supported" would involve several distinct research stages, none of which has been published.
A primary in vitro characterization would establish whether TED at physiologically plausible concentrations (typically nanomolar to low micromolar for bioactive peptides) produces any measurable effect on a relevant respiratory epithelial model — ideally a primary cell system or differentiated organoid rather than a transformed cell line, given that transformed cells show aberrant responses to peptide stimuli.[11] Outcome measures would need to be pre-specified: gene expression profiling, cytokine secretion, barrier integrity (transepithelial electrical resistance), or proliferation indices, depending on the hypothesis being tested. Any positive signal would require replication and dose-response characterization before interpretation.
Stability data are also absent from the public record. TED contains an aspartyl residue (Asp), and Asp-X sequences in peptides are known to be susceptible to aspartyl isomerization and succinimide intermediate formation under certain pH and temperature conditions — a degradation pathway that has been well-characterized in the antibody and peptide drug literature.[12] Whether the Glu-Asp C-terminal sequence in TED undergoes this modification at a rate relevant to experimental timescales has not been published. Researchers working with this compound should include appropriate analytical controls (HPLC purity checks at experimental timepoints) to confirm that observed results reflect the intact TED sequence rather than a degradation product.
Until compound-specific data exist, the appropriate posture for any laboratory working with Chonluten is to treat it as a structurally characterized research reagent of unknown biological activity — which is precisely what the current literature supports, and no more.
